ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
ARS Pharmaceuticals (SPRY), a biopharmaceutical company focused on protecting patients from severe allergic reactions and anaphylaxis, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place from January 13-16, 2025, in San Francisco.
Co-Founder, President and CEO Richard Lowenthal is scheduled to present on Wednesday, January 15, 2025, at 7:30 a.m. PT. The company's management team will also engage in one-on-one investor meetings during the event. A live webcast of the presentation will be accessible through the company's website's Investors & Media section, with the recording remaining available for 90 days afterward.
ARS Pharmaceuticals (SPRY), una società biopharmaceutica focalizzata sulla protezione dei pazienti da gravi reazioni allergiche e anafilassi, ha annunciato la sua prossima partecipazione al 43° Conferenza Annuale J.P. Morgan Healthcare. La conferenza si svolgerà dal 13 al 16 gennaio 2025 a San Francisco.
Il co-fondatore, presidente e CEO Richard Lowenthal è programmato per presentare mercoledì 15 gennaio 2025 alle 7:30 ora del Pacifico. Il team di gestione dell'azienda parteciperà anche a incontri individuali con gli investitori durante l'evento. Una trasmissione web in diretta della presentazione sarà accessibile attraverso la sezione Investitori & Media del sito web dell'azienda, con la registrazione che rimarrà disponibile per 90 giorni dopo.
ARS Pharmaceuticals (SPRY), una compañía biofarmacéutica enfocada en proteger a los pacientes de reacciones alérgicas severas y anafilaxis, ha anunciado su participación en la 43.ª Conferencia Anual de J.P. Morgan Healthcare. La conferencia se llevará a cabo del 13 al 16 de enero de 2025 en San Francisco.
El cofundador, presidente y director ejecutivo Richard Lowenthal está programado para presentar el miércoles 15 de enero de 2025 a las 7:30 a.m. PT. El equipo de gestión de la compañía también participará en reuniones individuales con inversores durante el evento. Una transmisión web en vivo de la presentación estará disponible a través de la sección de Inversores y Medios del sitio web de la compañía, con la grabación que permanecerá accesible durante 90 días después.
ARS Pharmaceuticals (SPRY), 심각한 알레르기 반응 및 아나필락시스로부터 환자를 보호하는 데 초점을 맞춘 생물 제약 회사가 제43회 연례 J.P. Morgan Healthcare 컨퍼런스에 참여할 예정이라고 발표했습니다. 이 컨퍼런스는 2025년 1월 13일부터 16일까지 샌프란시스코에서 개최됩니다.
공동 창립자이자 대통령, CEO인 Richard Lowenthal는 2025년 1월 15일 수요일 오전 7시 30분 PT에 발표할 예정입니다. 회사의 경영진 팀은 또한 행사 중에 개별 투자자 회의에 참여할 예정입니다. 발표의 실시간 웹캐스트는 회사 웹사이트의 투자자 및 미디어 섹션을 통해 접근할 수 있으며, 녹화본은 이후 90일 동안 이용 가능합니다.
ARS Pharmaceuticals (SPRY), une entreprise biopharmaceutique axée sur la protection des patients contre de sévères réactions allergiques et l'anaphylaxie, a annoncé sa prochaine participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. La conférence se déroulera du 13 au 16 janvier 2025 à San Francisco.
Le co-fondateur, président et PDG Richard Lowenthal est prévu pour présenter le mercredi 15 janvier 2025 à 7h30 PT. L'équipe de direction de l'entreprise participera également à des réunions individuelles avec les investisseurs pendant l'événement. Une diffusion en direct de la présentation sera accessible via la section Investisseurs & Médias du site Web de l'entreprise, l'enregistrement restant disponible pendant 90 jours par la suite.
ARS Pharmaceuticals (SPRY), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, Patienten vor schweren allergischen Reaktionen und Anaphylaxie zu schützen, hat seine bevorstehende Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Die Konferenz findet vom 13. bis 16. Januar 2025 in San Francisco statt.
Der Mitbegründer, Präsident und CEO Richard Lowenthal wird am Mittwoch, den 15. Januar 2025, um 7:30 Uhr PT präsentieren. Das Management-Team des Unternehmens wird während der Veranstaltung auch Einzelgespräche mit Investoren führen. Ein Live-Streaming der Präsentation wird über den Bereich Investoren & Medien auf der Website des Unternehmens zugänglich sein, wobei die Aufzeichnung 90 Tage lang verfügbar bleibt.
- None.
- None.
SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 in San Francisco.
Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma, will present on Wednesday, January 15, 2025, at 7:30 a.m. PT. Company management will also participate in one-on-one meetings with investors.
A live webcast of the presentation will be available in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® 2 mg (trade name EURneffy® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
ARS Investor Contacts:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com
ARS Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com
FAQ
When is ARS Pharmaceuticals (SPRY) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access SPRY's presentation at the J.P. Morgan Healthcare Conference?
What is the duration of the 2025 J.P. Morgan Healthcare Conference where SPRY will present?
Will SPRY management be available for individual investor meetings at the conference?
